Search results
Results from the WOW.Com Content Network
Shares of Amgen (NASDAQ: AMGN) are down by 6% in the last 30 days as I write this -- a larger-than-normal amount for a large pharma company's stock to fall, especially considering that the market ...
Lastly, Amgen is an excellent income stock, having increased its annual dividend per share by 249% in the past decade. Amgen still has a long pipeline and will continue to develop newer products.
For premium support please call: 800-290-4726 more ways to reach us
Amgen (NASDAQ: AMGN) stock is up 13% this year but has struggled to break out above a tight trading range in recent months. Despite a string of solid earnings reports from the biotechnology giant ...
Amgen (AMGN) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock ...
Amgen shares closed at $287.87 on Wednesday, down about 9% from earlier this month, when analysts at Cantor Fitzgerald said their review of Phase 1 MariTide data showed a drop in bone mineral ...
For premium support please call: 800-290-4726 more ways to reach us
Amgen (AMGN) beats Q2 estimates for both earnings and sales. It maintains its previously-issued sales guidance while raising the earnings range. Stock dips.